Bacillus amyloliquefaciens Fmb50 Alleviates Hyperglycemia by Reshaping Gut Structures and Mitigating Metabolic Disorders in Type 2 Diabetic Mice.

Fmb50 and its spores reduced fasting blood glucose and improved oral glucose tolerance in T2DM mice.

• Both vegetative cells (Fmb50) and spore forms were tested in a type 2 diabetic mouse model.
• Fasting blood glucose levels were significantly reduced following treatment with Fmb50 and its spores.
• Oral glucose tolerance was improved, indicating enhanced glucose metabolism.
• The study used a T2DM mouse model to assess hypoglycemic mechanisms.

Fmb50 and its spores decreased serum and liver metabolic indicators associated with T2DM.

• Serum glucose and glycated serum protein (GSP) levels were decreased following treatment.
• Liver indicators including triglycerides (TG) and total cholesterol (TC) were reduced.
• Hepatic lipid accumulation was inhibited by both Fmb50 and its spores.
• These effects suggest systemic metabolic improvement beyond glycemic control alone.

Fmb50 and its spores reversed tissue injuries in liver, pancreas, epididymal adipose tissue, and intestinal barrier in T2DM mice.

• Histological or functional injuries in liver, pancreas, and epididymal adipose tissue were reversed by treatment.
• Intestinal barrier integrity was restored by both Fmb50 and its spores.
• Repair of the intestinal barrier was identified as a key mechanism in alleviating T2DM.
• Inflammatory response was inhibited as part of the mechanism of action.

Fmb50 and its spores activated the hepatic AMPK pathway and reduced protein levels of G6Pase and PEPCK.

• The hepatic AMP-activated protein kinase (AMPK) pathway was activated following treatment.
• Protein levels of glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), key gluconeogenic enzymes, were reduced.
• These effects were attributed to regulation of intestinal microbiota, inhibition of inflammation, and repair of intestinal barrier.
• Activation of AMPK and suppression of gluconeogenic enzymes represent a mechanistic link between gut changes and hepatic glucose output.

Fmb50 and its spores reshaped the gut microbiota and altered short-chain fatty acid (SCFA) profiles in T2DM mice.

• 16S rRNA analysis was used to assess gut microbiota composition changes.
• SCFA detection was performed to evaluate metabolic outputs of gut microbiota.
• Gut microbiota dysbiosis associated with T2DM was modulated by Fmb50 treatment.
• The gut-SCFAs-liver axis was identified as the primary mechanism through which insulin resistance was mitigated.

Fmb50 and its spores demonstrated the ability to colonize the intestine of T2DM mice.

• Intestinal colonization by Fmb50 and its spores was confirmed in the mouse model.
• Colonization capacity was considered important for the sustained alleviation of T2DM.
• Both vegetative and spore forms were capable of colonization.
• This colonization ability supports the potential for Fmb50 as a functional food ingredient for individuals with hyperglycemia and insulin resistance.

Fmb50 is a surfactin-producing strain of Bacillus amyloliquefaciens with potential as a functional food candidate for hyperglycemia management.

• Fmb50 was identified as a surfactin-producing strain, which may contribute to its bioactive properties.
• The study investigated both vegetative cell and spore forms to characterize hypoglycemic mechanisms.
• Authors suggest Fmb50 'may be a promising candidate for functional food development in individuals with hyperglycemia and insulin resistance.'
• Findings are presented in the context of T2DM being accompanied by glucose metabolism disorder and intestinal microbial dysbiosis.